Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Extracorporeal Membrane Oxygenation Machine Market
The global Extracorporeal Membrane Oxygenation (ECMO) machine market was valued at USD 10,000 Million in 2025 and is projected to reach USD 18,771.37 Million by 2035, expanding at a compound annual growth rate (CAGR) of 6.5% over the forecast period.
Market size
Growth trajectory through 2035
Extracorporeal Membrane Oxygenation Machine Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2020 COVID-19 Pandemic Impact
- ECMO adoption surged during the COVID-19 pandemic as a rescue therapy for severe acute respiratory failure, with studies showing reduced mortality rates (approximately 46%) compared to conventional ventilation alone. Initial reports from China in early 2020 highlighted ECMO’s role in restoring blood oxygenation in critically ill SARS-CoV-2 patients, particularly in the ~3% of severe cases where standard ventilation proved insufficient.
-
Development 02 Technological Advancements
- Continuous improvements in ECMO systems, including miniaturized devices for neonatal/pediatric use and enhanced oxygenators, have expanded clinical applications. Collaborations between medical device companies and research institutes have accelerated the development of upgraded ECMO technologies, supporting broader adoption in critical care settings.
-
2023 Regional Adoption Trends
- In 2023–2025, India saw a sharp rise in ECMO adoption, with approximately 160 machines sold and 54 centers actively performing ECMO procedures nationwide. The United States remains a key market, with a national survey of 274 adult ECMO centers (2025) showing all 136 responding hospitals offer ECMO, including both veno-arterial (V-A) and veno-venous (V-V) modalities. Nearly half of these centers operate 24/7 ECMO retrieval programs, enabling mobile/remote deployments.
-
Development 04 Clinical Research Expansion
- The growing focus on ECMO’s efficacy in neonatal and pediatric care has driven market growth, with survival rates reported at 75% for neonatal respiratory failure, 56% for pediatric cases, and 55% for adults in ELSO registry data. These outcomes underscore ECMO’s role as a life-saving intervention in critical care.
Emerging opportunities added
- Growth in neonatal and pediatric ECMO applications Increasing focus on improving neonatal and pediatric care is creating opportunities for ECMO adoption in these segments. Advances in miniaturized ECMO systems are enabling safer and more effective use in younger patients.
- Expansion of mobile and remote ECMO programs The development of mobile ECMO units and remote deployment capabilities is opening new avenues for market growth. These programs enhance access to ECMO therapy in underserved or geographically remote areas, supporting timely intervention.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 59.5% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High cost of ECMO systems and procedures
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
COVID-19 Pandemic Impact: ECMO adoption surged during the COVID-19 pandemic as a rescue therapy for severe acute respiratory failure, with studies showing reduced mortality rates (approximately 46%) compared to conventional ventilation alone. Initial reports from China in early 2020 highlighted ECMO’s role in restoring blood oxygenation in critically ill SARS-CoV-2 patients, particularly in the ~3% of severe cases where standard ventilation proved insufficient
+3 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 117-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Extracorporeal Membrane Oxygenation Machine Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of ECMO Machines, Software holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Cardiac Surgery, Respiratory Failure, Neonatal/Pediatric Critical Care applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do GSK plc, Pfizer Inc, Johnson & Johnson and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of respiratory and cardiac disorders) and top restraints (led by High cost of ECMO systems and procedures), with quantified CAGR impact?
- What regulatory shifts and 4 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of respiratory and cardiac disorders The increasing global burden of respiratory illnesses, including severe acute respiratory conditions, is driving demand for advanced life-support technologies such as ECMO. Respiratory tract infections account for a significant proportion of mortality, particularly in pediatric patients, necessitating rescue therapies lik…
- Expansion of critical care capacity Hospitals are expanding their critical care infrastructure, with many regions investing in specialized ECMO programs to address high mortality risks associated with severe respiratory and cardiac conditions. This trend is contributing to broader adoption of ECMO machines in clinical practice.
- Technological advancements in ECMO systems Continuous improvements in oxygenators, circuit designs, and system integration are enhancing the efficacy and safety of ECMO machines. These advancements are supporting broader clinical applications and driving market growth.
Restraints
Holding it back
- High cost of ECMO systems and procedures The substantial capital and operational costs associated with ECMO machines and their maintenance pose a barrier to adoption, particularly in resource-constrained healthcare settings. This limits market penetration in lower-income regions.
- Complexity of ECMO operation and training requirements ECMO therapy requires specialized training for healthcare professionals, including perfusionists and intensivists. The steep learning curve and need for ongoing education can slow adoption rates and limit scalability.
- Limited reimbursement policies in certain regions Inconsistent reimbursement frameworks for ECMO procedures across different countries and healthcare systems can restrict market growth. Payers' reluctance to cover costs may deter hospitals from investing in ECMO infrastructure.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of respiratory and cardiac disorders | +2.9% | Global | 2025–2035 |
| Expansion of critical care capacity | +1.8% | Global | 2025–2035 |
| Technological advancements in ECMO systems | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost of ECMO systems and procedures | −1.2% | Global | 2025–2029 |
| Complexity of ECMO operation and training requirements | −0.8% | Global | 2025–2029 |
| Limited reimbursement policies in certain regions | −0.6% | Global | 2025–2029 |
Total 3 ECMO Machines 67% Software 33% The ECMO machine market is segmented by product type and application, reflecting diverse clinical and operational requirements across healthcare settings.
Revenue share by type · 2025 base year
% OF $10.00 BN EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET · 2 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Extracorporeal Membrane Oxygenation Machine Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
ECMO Machines
-
Software
By application
-
Cardiac Surgery
-
Respiratory Failure
-
Neonatal/Pediatric Critical Care
-
Emergency Resuscitation
-
Bridge to Transplant or Recovery
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~43.0% in 2025. The region is characterized by a strong presence of advanced hospital networks and critical care facilities, supported by high healthcare expenditure. The United States, in particular, has a well-est…
Per-region detail
-
North America
The region is characterized by a strong presence of advanced hospital networks and critical care facilities, supported by high healthcare expenditure. The United States, in particular, has a well-established ECMO infrastructure with a significant number of centers offering both veno-arterial and veno-venous ECMO
-
Europe
Europe benefits from robust healthcare systems and increasing investment in specialized ECMO programs. The region is seeing growth in clinical research and collaborations between medical device companies and research institutes, accelerating the development of advanced ECMO technologies
-
Asia-Pacific
The Asia-Pacific region is experiencing rapid growth in ECMO adoption, driven by rising healthcare expenditure and increasing prevalence of respiratory and cardiac disorders. Countries like India are witnessing a sharp rise in ECMO machine sales and utilization, reflecting growing clinical acceptance
-
Latin America
Growth in Latin America is supported by expanding critical care capacity and increasing awareness of ECMO therapy. However, market expansion is tempered by economic constraints and limited reimbursement policies in some countries
-
Middle East & Africa
The region presents opportunities for ECMO market growth, particularly in urban centers with advanced healthcare infrastructure. Increasing healthcare investments and partnerships with international medical technology providers are contributing to market development
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The ECMO machine market is moderately concentrated, with a mix of multinational medical technology firms and specialized ECMO providers competing for market share. Innovation and strategic partnerships are key differentiators in this evolving landscape.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
GSK plc
Rank 01Share est. ~16%Revenue $38B FYHQ UK · London -
Pfizer Inc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Holding AG
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Novartis AG
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Merck & Co., Inc
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
AbbVie Inc
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Eli Lilly and Company
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the growth of global extracorporeal membrane oxygenation machine market?
The extracorporeal membrane oxygenation machine market size had crossed USD 556 Million in 2020 and will observe a CAGR of more than 2.41% up to 2027. The growing target patient population and rising awareness about early diagnosis are fueling the growth of the market. -
• What is the size of the Asia Pacific extracorporeal membrane oxygenation machine industry?
Asia Pacific held more than 37% of the extracorporeal membrane oxygenation machine market revenue share in 2020. -
• What are the major factors expected to restrict the growth in extracorporeal membrane oxygenation machine market, globally?
Declining reimbursements, a lack of infrastructure, particularly in emerging and impoverished nations, and possible dangers connected with radiation exposure are all projected to stymie market expansion. -
• What is the CAGR of extracorporeal membrane oxygenation machine market?
The global extracorporeal membrane oxygenation machine market registered a CAGR of 2.41% from 2022 to 2029. -
• Which are the top companies to hold the market share in extracorporeal membrane oxygenation machine market?
Key players profiled in the report include Fresenius Medical care AG & Co. KGaA, Getinge Group, Medtronic plc; Sorin Group, Terumo Cardiovascular Systems Corporation, MAQUET Holding B.V. & Co. KG, Medos Medizintechnik AG, Nipro Medical Corporation, Microport Scientific Corporation. -
• What is the leading application of the extracorporeal membrane oxygenation machine market?
The Respiratory sector is projected to be the fastest-growing segment in the extracorporeal membrane oxygenation machine market. -
• Which is the largest regional market for extracorporeal membrane oxygenation machine market?
Asia Pacific is the largest regional market for the extracorporeal membrane oxygenation machine market.
The Extracorporeal Membrane Oxygenation Machine Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.